

83. The method of claim 31 or 71 wherein the compound is a small molecule.

84. The method of claim 31 or 71 wherein the compound is a peptide.

---

#### REMARKS

In response to the Restriction Requirement, Applicant elects to pursue the subject matter of the claims of group IV, claims 31-32 and 71, drawn to a method of modulating an immune response, classified in class 424, subclass 193.1.

By this amendment, the non-elected claims have been canceled, without prejudice to Applicant's right to pursue claims to the subject matter of these claims in other applications, Claims 31 and 71 have been amended, and new claims 75 - 84 have been added, to more particularly point out and distinctly claim the invention. A marked-up version of the claim amendments, with additions indicated by underlining and deletions indicated by brackets, is provided herewith as Exhibit A.

The new and amended claims are fully supported in the specification as originally filed. For example, support for the new claims can be found as follows:

Claims	Recitation	Support
31, 71	<ul style="list-style-type: none"> <li>recites the method for modulating an immune response using a compound <u>other than a complex of a heat shock protein and a peptide</u>.</li> </ul>	Section 5.6 page 49, line 4 through page 50, line 24.
	<ul style="list-style-type: none"> <li>recites the method for modulating an immune response comprising administering to a <u>human</u>.</li> </ul>	page 25, lines 14-15; page 67, lines 32-33; page 68, lines 3-4.
75	<ul style="list-style-type: none"> <li>recites the method of claim 71 wherein the compound is an agonist which increases <math>\alpha 2M</math> receptor activity.</li> </ul>	page 9, line 26; page 26, lines 1-7; page 26, lines 33-34; page 29, lines 34-36; page 49, lines 22-24.
76	<ul style="list-style-type: none"> <li>recites the method of claim 31 or 71 wherein the compound is an antagonist which decreases <math>\alpha 2M</math> receptor activity.</li> </ul>	page 9, lines 33-34; page 49, lines 24-26; page 49, lines 33-36.
77	<ul style="list-style-type: none"> <li>recites the method of claim 31 wherein the compound is an antibody specific for <math>\alpha 2M</math>.</li> </ul>	page 9, lines 30-33; page 49, lines 33-36.
78	<ul style="list-style-type: none"> <li>recites the method of claim 31 or 71 wherein the compound is an antibody specific for <math>\alpha 2M</math> receptor.</li> </ul>	page 26, lines 1-3; page 49, lines 11-13.
79	<ul style="list-style-type: none"> <li>recites the method of claim 31 wherein the compound is an antibody specific for a heat shock protein.</li> </ul>	page 9, line 36; page 49, lines 24-26.
80	<ul style="list-style-type: none"> <li>recites the method of claim 31, wherein the heat shock protein is gp96.</li> </ul>	page 1, lines 25-27; page 49, line 6.
81	<ul style="list-style-type: none"> <li>recites the method of claim 31 wherein the heat shock protein is Hsp70.</li> </ul>	page 1, lines 25-27; page 49, line 6.
82	<ul style="list-style-type: none"> <li>recites the method of claim 31 wherein the heat shock protein is Hsp90.</li> </ul>	page 1 lines 25-27; page 49, line 6.
83	<ul style="list-style-type: none"> <li>recites the method of claim 31 or 71 wherein the compound is a small molecule.</li> </ul>	page 9, lines 36-37; page 26, lines 21-26; page 29, line 30 through page 30, line 12.
84	<ul style="list-style-type: none"> <li>recites the method of claim 31 or 71 wherein the compound is a peptide.</li> </ul>	page 9, line 37 through page 10, line 1; page 7 line 24; page 51 line 8.

Applicant asserts that no new subject matter, as defined in 35 U.S.C. § 132, has been added with the addition of new claims. Claims 31, 32, 71, and 75 - 84, therefore, are now pending. A copy of the pending claims is included herewith as Exhibit B.

Applicant respectfully requests that the foregoing remarks and amendments made herein be entered into the record of the instant application. Please charge the required fee, as estimated on the accompanying amendment fee transmittal sheet, to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: April 1, 2002

Adriane M. Antler 32,605

Adriane M. Antler (Reg. No.)

By: Eileen E. Falvey 46,097

Eileen E. Falvey (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures



RECEIVED

APR 08 2002

TECH CENTER 1600/2900

**EXHIBIT A: MARKED-UP VERSION OF CLAIM AMENDMENTS**  
(Additions indicated by underlining and deletions indicated by brackets)

---

31. (amended) A method for modulating an immune response comprising administering to a [mammal] human a purified compound [that], other than a complex of a heat shock protein and a peptide, which compound modulates the interaction of a first heat shock protein with the alpha (2) macroglobulin receptor.

71. (amended) A method for modulating an immune response comprising administering to a [mammal] human a purified compound, other than a complex of a heat shock protein and a peptide, that binds to the [ $\alpha$ 2M] alpha (2) macroglobulin receptor, in an amount effective to modulate an immune response in the mammal.